CMS may put oncologic PET coverage in local hands

The Centers for Medicare & Medicaid Services (CMS) has proposed removing the national noncoverage decision for PET for FDA-approved oncologic applications. If the decision is finalized, local Medicare Administrative Contractors may determine coverage for new oncologic agents within their respective jurisdictions for PET.

The Medical Imaging & Technology Alliance (MITA) applauded the move. “We are encouraged by this first step in removing restrictions for Medicare beneficiaries to access PET procedures. A positive final decision will give cancer patients better access to cutting-edge tools physicians need to diagnose and manage cancer treatment,” said Gail Rodriguez, executive director of MITA, in a press release.

However, the proposal does not address PET tracers for cardiology and neurology. MITA encouraged CMS to expand the proposal to all disease areas appropriate for PET.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.